







Toxoplasmosis infection is very common, but symptomatic toxoplasmic encephalitis occurs in less than 10% of infected patients and primarily affects immunocompromised populations including HIV/AIDS patients, transplant recipients, and other immunosuppressed individuals.
The pathophysiology involves reactivation of dormant brain cysts from Toxoplasma gondii in immunocompromised hosts, presenting with characteristic CNS symptoms including headaches, confusion, weakness, lack of coordination, and seizures.
Diagnosis is supported by the Sabin-Feldman dye test (gold standard) and ELISA (most common) detecting anti-toxoplasma IgG and IgM antibodies, with immunohistochemistry used on biopsy tissue for definitive confirmation.
The distinction from primary CNS lymphoma is clinically critical because toxoplasmosis responds well to antibiotics while lymphoma carries poor prognosis and requires high-toxicity chemotherapy.
Multiparametric MRI sequences including DWI/ADC, perfusion imaging, and MR spectroscopy combined with functional imaging like FDG-PET provide high accuracy in noninvasive differentiation from similar-appearing lesions.
Biopsy remains the definitive diagnostic tool when noninvasive imaging and serologic tests are inconclusive, particularly important before committing to toxic lymphoma therapy.
Report the characteristic ring-enhancing lesions with concentric and eccentric 'target sign' enhancement in the basal ganglia and corticomedullary junction distribution, emphasize the absence of diffusion restriction on DWI/ADC, and note that while imaging is highly suggestive of toxoplasmosis, definitive diagnosis requires correlation with serology (Sabin-Feldman dye test or ELISA) or histopathology, particularly to exclude primary CNS lymphoma.